Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation : results from PROSPER and FINRISK 1997

Show full item record



Permalink

http://hdl.handle.net/10138/237142

Citation

Delles , C , Rankin , N J , Boachie , C , McConnachie , A , Ford , I , Kangas , A , Soininen , P , Trompet , S , Mooijaart , S P , Jukema , J W , Zannad , F , Ala-Korpela , M , Salomaa , V , Havulinna , A S , Welsh , P , Wurtz , P & Sattar , N 2018 , ' Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation : results from PROSPER and FINRISK 1997 ' , European Journal of Heart Failure , vol. 20 , no. 4 , pp. 663-673 . https://doi.org/10.1002/ejhf.1076

Title: Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation : results from PROSPER and FINRISK 1997
Author: Delles, Christian; Rankin, Naomi J.; Boachie, Charles; McConnachie, Alex; Ford, Ian; Kangas, Antti; Soininen, Pasi; Trompet, Stella; Mooijaart, Simon P.; Jukema, J. Wouter; Zannad, Faiez; Ala-Korpela, Mika; Salomaa, Veikko; Havulinna, Aki S.; Welsh, Paul; Wurtz, Peter; Sattar, Naveed
Other contributor: University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Research Programs Unit



Date: 2018-04
Language: eng
Number of pages: 11
Belongs to series: European Journal of Heart Failure
ISSN: 1388-9842
DOI: https://doi.org/10.1002/ejhf.1076
URI: http://hdl.handle.net/10138/237142
Abstract: Aims We investigated the association between quantified metabolite, lipid and lipoprotein measures and incident heart failure hospitalisation (HFH) in the elderly, and examined whether circulating metabolic measures improve HFH prediction.& para;& para;Methods and results Overall, 80 metabolic measures from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial were measured by proton nuclear magnetic resonance spectroscopy (n = 5341; 182 HFH events during 2.7-year follow-up). We repeated the work in FINRISK 1997 (n = 7330; 133 HFH events during 5-year follow-up). In PROSPER, the circulating concentrations of 13 metabolic measures were found to be significantly different in those who were later hospitalised for heart failure after correction for multiple comparisons. These included creatinine, phenylalanine, glycoprotein acetyls, 3-hydroxybutyrate, and various high-density lipoprotein measures. In Cox models, two metabolites were associated with risk of HFH after adjustment for clinical risk factors and N-terminal pro-B-type natriuretic peptide (NT-proBNP): phenylalanine [hazard ratio (HR) 1.29, 95% confidence interval (CI) 1.10-1.53; P = 0.002] and acetate (HR 0.81, 95% CI 0.68-0.98; P = 0.026). Both were retained in the final model after backward elimination. Compared to a model with established risk factors and NT-proBNP, this model did not improve the C-index but did improve the overall continuous net reclassification index (NRI 0.21; 95% CI 0.06-0.35; P = 0.007) due to improvement in classification of non-cases (NRI 0.14; 95% CI 0.12-0.17; P
Subject: Metabolomics
Advanced lipoprotein profiling
Heart failure
PROSPER
Phenylalanine
FINRISK
ASSOCIATION TASK-FORCE
PRACTICE GUIDELINES
NATRIURETIC PEPTIDE
EUROPEAN-SOCIETY
LIPID-METABOLISM
RISK PROSPER
DIAGNOSIS
PRAVASTATIN
MANAGEMENT
ADULTS
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Nuclear_magnetic_resonance_based.pdf 1.844Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record